Jakson I, Hirschberg AL, Gidlöf SB. Endometriosis and menopause: management strategies based on clinical scenarios. Acta Obstetricia et Gynecologica Scandinavica, 2023. https://doi.org/10.1111/aogs.14583
Key takeaways
- Menopause does not reliably cure endometriosis. For most women symptoms improve, but the condition can persist or cause new symptoms after menopause in a meaningful minority of cases.
- If you have a history of endometriosis and are considering HRT, the type matters significantly. Current UK clinical guidance recommends combined HRT rather than oestrogen-only, even for women who have had a hysterectomy.
- The evidence base for managing this combination of conditions is genuinely limited, which is why individualised specialist assessment is more important here than almost anywhere else in menopause care.
The question most women with endometriosis ask about menopause
"Will menopause finally fix this?"
After years of managing a condition that takes an average of seven to ten years to diagnose in the UK, and that has often been dismissed, minimised, or treated inadequately during that time, this is not an unreasonable thing to hope. Menopause is oestrogen-dependent in the same way endometriosis is. The logic seems sound.
If you have spent years fighting to have your symptoms taken seriously, you deserve an honest answer at this stage of your health journey. That answer is more nuanced than you may have been told, and understanding it is what allows you to make properly informed decisions about what comes next.
The myth: menopause cures endometriosis
For most women with endometriosis, menopause does bring significant symptom improvement. When oestrogen declines, the hormonal environment that drives endometrial tissue growth and inflammation changes, and for many women the pain and bleeding that defined their experience reduces substantially.
But "most women" is not "all women." A 2025 literature review in the Journal of Clinical Medicine confirmed that endometriosis can persist, and in some cases become more symptomatic, after menopause. Postmenopausal endometriosis affects an estimated 2 to 4% of women. Many of these women were never formally diagnosed before menopause, having lived with symptoms for decades without a clear explanation.
The reason endometriosis can persist despite low systemic oestrogen levels is partly explained by the lesions themselves. Endometriotic tissue has been found to contain aromatase, an enzyme that enables local oestrogen production independent of the ovaries. A low-oestrogen systemic environment does not necessarily mean zero oestrogen at the site of the lesions. This is why some women experience continuing or new pelvic symptoms after menopause that turn out to be endometriosis-related.
In rare cases, endometriosis can also develop for the first time after menopause. This is not well understood and is poorly quantified in the literature. What it means practically is that new pelvic symptoms after menopause, in a woman with a history of endometriosis, should always be assessed by a specialist rather than attributed to other causes without investigation.
What perimenopause actually feels like when you have endometriosis
This is the part that most content about endometriosis and menopause misses entirely, and it is the part that women in this group most often describe as the hardest.
Perimenopause is not a smooth hormonal decline. It is a period of significant hormonal fluctuation, where oestrogen levels swing irregularly before the eventual sustained fall. For women with endometriosis, these fluctuations can sometimes reactivate lesions and worsen symptoms. A 2023 clinical scenarios paper in Acta Obstetricia et Gynecologica Scandinavica confirmed that perimenopause can see symptom recurrence or intensification in women with endometriosis, driven by this hormonal volatility. The transition phase, rather than postmenopause, is often when women feel most let down.
If you are in perimenopause, noticing worsening pain or symptom flares, and feeling confused or frustrated because you expected this stage to be better; it does not mean your endometriosis is permanently worse or that menopause will not eventually bring relief. It may mean you are in the most turbulent part of the transition.
Perimenopause is also harder to recognise when you have endometriosis, because the symptom overlap is substantial: irregular bleeding, pelvic pain, mood changes, fatigue, and sleep disruption are common to both. If you are uncertain whether what you are experiencing is menopause, endometriosis, or both, that uncertainty is clinically legitimate, not a failure to understand your own body.
Endometriosis and early menopause: the link that often goes unmentioned
Research suggests that endometriosis may bring menopause earlier for some women. A large-scale analysis drawing on data from the Nurses' Health Study II, involving over 100,000 women, found that laparoscopically confirmed endometriosis was associated with a 50% greater risk of early natural menopause, before the age of 45.
The exact reasons are not fully understood, but possible explanations include chronic inflammation affecting the ovaries and a reduction in the number of eggs available, either because of the condition itself or as a result of surgery. Repeated surgeries for endometriomas (ovarian cysts caused by endometriosis) can remove healthy ovarian tissue alongside the cysts, potentially reducing the number of remaining follicles and bringing the menopausal transition forward. A prospective study published in BMC Women's Health found that high FSH and low AMH levels, both markers of reduced ovarian reserve, were associated with bone mineral density loss in perimenopausal women with endometriosis.
If you have endometriosis and are approaching your mid to late 30s or 40s, it is worth knowing that your menopausal transition may begin earlier than you expect. Early menopause carries its own health implications, particularly for bone and cardiovascular health, and benefits from proactive specialist management.
Symptoms to watch for after menopause if you have endometriosis
The general expectation after menopause is that pelvic pain improves. For most women it does. But new or returning pelvic symptoms after menopause should not be self-managed or assumed to be a normal continuation of earlier symptoms.
Symptoms that warrant specialist assessment include:
- New or recurring pelvic pain after at least 12 months without periods
- Abnormal bleeding (any vaginal bleeding after menopause should always be assessed)
- Pain on urination or bowel movements
- A noticeable pelvic mass or new abdominal symptoms (e.g. pain, cramps, bloating)
- Significant fatigue combined with pelvic symptoms
Some of these overlap with genitourinary syndrome of menopause (vaginal dryness, urinary urgency, and discomfort), which is common and benign. The distinction can be difficult to make without clinical assessment, which is precisely the point: these symptoms need a specialist to evaluate them properly, not a search engine.
HRT with endometriosis history: what clinical guidance says
HRT is not ruled out for women with a history of endometriosis. For many women who experience significant menopause symptoms, the benefits of appropriate HRT will outweigh the risks. But the type of HRT matters significantly, and this is the clinical nuance that most content on this topic fails to convey.
Why combined HRT is recommended over oestrogen-only:
Endometriosis lesions are oestrogen-sensitive. Oestrogen-only HRT may reactivate residual lesions in women with endometriosis history, even after hysterectomy, because lesions can remain in the pelvis regardless of whether the uterus has been removed. Adding a progestogen to the HRT regimen counteracts this oestrogen-stimulating effect.
The British Menopause Society's 2026 clinical guidance on induced menopause in women with endometriosis is explicit: continuous combined HRT is preferred for women with endometriosis history, including those who have had a hysterectomy. Tibolone (a synthetic steroid with combined hormonal activity) is listed as an alternative, though there are concerns around its safety with regard to clotting and breast cancer risk.. For hysterectomised women with little or no residual disease, oestrogen-only HRT may be considered after an initial period of combined HRT, but this is a case-by-case specialist decision, not a general recommendation.
A 2025 systematic review in the Journal of Clinical Medicine, examining 43 studies in a PRISMA-compliant analysis, found that in a cohort of over 20,000 postmenopausal women, combined oestrogen-progestogen HRT and tibolone did not show a statistically significant increase in the risk of endometriosis-associated cancer. Oestrogen-alone did show a higher risk signal (HR 2.898 in the cohort data).
What this means practically:
If you are considering HRT and have a history of endometriosis, the conversation is not whether HRT is possible. It is which formulation is appropriate for your specific history, the extent of any residual disease, and the degree of surgical treatment you have had. This requires a specialist who has time to take a full history and make an individually assessed recommendation.
A note on the evidence:
The research team behind the Acta Obstetricia and Gynecologica Scandinavica clinical scenarios paper (2023) made an important point that is worth stating clearly: no published data exists on managing menopausal symptoms in women with endometriosis undergoing normal menopausal transition. Almost all available evidence comes from more severe or surgically managed cases. This means that while the clinical guidance from the BMS represents the best current framework available, it is based on limited and evolving evidence, and shared decision-making with a knowledgeable specialist is the appropriate standard of care for this group.
The malignant transformation question: honest about a rare but real risk
The question of whether endometriosis increases cancer risk after menopause is one that many women in this group carry, often quietly. It deserves a precise answer.
Endometriosis is associated with a slightly elevated risk of two specific ovarian cancer types: clear cell carcinoma and endometrioid ovarian carcinoma. This is a real association, but the absolute risk is small and the evidence base is limited.
What the evidence most clearly supports is that the risk is not distributed evenly. The 2025 systematic review in the Journal of Clinical Medicine identified three recurring risk conditions in the literature: a history of endometriosis, prior definitive gynaecological surgery before menopause, and prolonged oestrogen-only HRT. The finding that combined HRT and tibolone do not appear to significantly increase this risk is one of the most clinically actionable pieces of evidence available on this topic. It reinforces, from a cancer-risk perspective, the same recommendation that applies from an endometriosis-reactivation perspective: combined HRT is the preferred formulation.
“The conclusion to draw is not alarm. It is the importance of monitoring, specialist assessment when new symptoms arise, and ensuring any HRT is the right formulation for your history. These are protective responses, not reasons to avoid treatment.”
Non-hormonal approaches to managing persistent symptoms
Not all women with endometriosis history will choose HRT, or will be suitable for it, and pain can persist even when hormonal management is appropriate. Several non-hormonal approaches have evidence supporting their use.
Pain management:
NSAIDs (non-steroidal anti-inflammatory medications such as Naproxen or Ibuprofen) remain a first-line option for mild to moderate persistent pelvic pain. For women with postmenopausal endometriosis pain that does not respond to standard management, a specialist may consider aromatase inhibitors (e.g Letrozole), which suppress residual local oestrogen production in endometriotic lesions. This is a specialist-prescribed option, not a self-management strategy, and is outside the scope of general guidance.
Surgery is described in the academic literature as the preferred option for symptomatic postmenopausal endometriosis, both to relieve symptoms and to allow tissue to be examined to rule out concerning changes. The decision about surgical management requires specialist evaluation.
Persistent pain and central sensitisation:
For some women, pelvic pain continues after menopause even when the hormonal environment has changed and lesions are quiescent. Over time, the nervous system can become sensitised to pain signals, meaning that even when the underlying hormonal drivers reduce, pain pathways remain active. This is a recognised physiological process, not imagined pain, and it responds better to a multi-modal approach than to hormonal management alone.
CBT and mindfulness:
CBT and mindfulness-based approaches have shown meaningful benefits for pain perception and quality of life in women with chronic pelvic pain. They work best as part of a broader treatment plan rather than as standalone solutions. Voy offers structured CBT as part of its comprehensive menopause care, which may be particularly relevant for women managing both menopause symptoms and persistent pain.
Bone health: an underappreciated concern for women with endometriosis entering menopause
Women with endometriosis may carry a higher bone health risk into the menopausal transition than the general population, for several compounding reasons.A prospective study published in BMC Women's Health found that high FSH (follicle-stimulating hormone) and low AMH (anti-mullerian hormone) levels, both markers of reduced ovarian reserve, were associated with bone mineral density loss in perimenopausal women with endometriosis.
GnRH agonists, a common treatment for endometriosis, suppress oestrogen and reduce bone density during treatment. Repeated surgical treatment for endometriomas may reduce ovarian reserve and bring forward the oestrogen-depleted state that accelerates bone loss. The BMC Women's Health prospective study found that reduced ovarian reserve in perimenopausal women with endometriosis was associated with lower bone mineral density, and suggested bone density scanning is appropriate for this population.
BMS 2026 guidance includes bone protection as a specific consideration in induced and surgical menopause in women with endometriosis. HRT, in the right formulation, addresses both symptom management and bone protection simultaneously.
If you have had GnRH treatment or multiple ovarian surgeries, a bone density scan is worth discussing with your specialist as a baseline assessment. If it is not something that is routinely offered; it is something worth asking for.
Getting the right support
The combination of endometriosis and menopause is one of the most clinically nuanced areas in women's health. The evidence is limited, the individual variation is substantial, and the questions women carry into this transition are specific, sophisticated, and often unanswered by generic guidance.
This is not a situation for self-management, or for a ten-minute GP appointment where endometriosis history is a footnote. It requires a clinician who has time to take a full history, understand the extent and treatment history of your endometriosis, consider the HRT formulation question in the context of your individual risk profile, assess bone health implications, and build a monitoring plan.
If your menopause was triggered by surgery for endometriosis rather than through natural menopausal transition, the additional considerations around medically induced menopause, including the timing of HRT and the long-term health implications of early surgical menopause, are covered separately.
88% of Voy members felt more hormonally balanced at three months, compared to 62% receiving standard care (presented at The Menopause Society 2025, forthcoming in Climacteric). That gap reflects what properly personalised, specialist-led care produces. For women managing menopause with endometriosis in the background, personalisation is not a nice-to-have. It is what makes the difference between a treatment plan that works and one that makes things worse.
Voy's menopause consultations are 45 minutes with BMS-trained (British Menopause Society) specialists: clinicians who have the time and expertise to hold the full complexity of your history and make treatment decisions that fit your individual situation.
